SCHEMBL478244

SCHEMBL478244

O=C(C=Cc1ccccc1)/C=C/c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 1.00
CYP2C9 P11712 3/20 1.00
F3 P13726 3/20 1.00
CYP1A2 P05177 3/20 1.00
PLIN1 O60240 2/20 1.00
LMNA P02545 2/20 1.00
RECQL P46063 2/20 1.00
PLIN5 Q00G26 2/20 1.00
ABHD5 Q8WTS1 2/20 1.00
CYP2D6 P10635 2/20 1.00
ALDH1A1 P00352 2/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HDAC3 O15379 2/20 0.73
HDAC4 P56524 2/20 0.73
HDAC1 Q13547 2/20 0.73
HDAC2 Q92769 2/20 0.73
HDAC8 Q9BY41 2/20 0.73
HDAC6 Q9UBN7 2/20 0.73
TNKS O95271 1/20 0.73
HCAR2 Q8TDS4 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20856054 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL28435740 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL20518814 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL22146 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL20846 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL28181 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL5347650 1.00 MAPT (1.00) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL187662 0.97 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL21879664 0.97 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1
SCHEMBL7265797 0.97 MAPT (0.95) MAPTCYP2C9F3CYP1A2PLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100579965-C Process for preparing N-heteroaryl-N-arylamines by reacting N-aryl carbamates with haloheteroaryls and analogous processes VERTEX PHARMA CO LTD 2010-01-13 CN claimed
CN-118488944-A Nitrogen-containing heterocyclic compound having Nrf2 activation 中外制药株式会社 2024-08-13 CN disclosed
CN-118317774-A Pharmaceutical compositions comprising quinazoline compounds 安斯泰来制药株式会社 2024-07-09 CN disclosed
CN-117957225-A Compounds for targeting degradation of IRAK4 proteins 渤健马萨诸塞州股份有限公司 2024-04-30 CN disclosed
CN-111491914-B Novel cationic quaternary ammonium compound, composition comprising the same and process for producing the same 罗地亚经营管理公司 2024-04-26 CN disclosed
EP-3755760-B1 PROCESSES FOR THE MANUFACTURE OF SECONDARY FATTY ALCOHOLS, INTERNAL OLEFINS AND INTERNAL OLEFIN SULFONATES SPECIALTY OPERATIONS FRANCE (FR) 2024-02-21 EP disclosed
CN-112384491-B Method for producing alpha-fluoroacrylic acid compound 大金工业株式会社 2024-02-13 CN disclosed
CN-117483004-A Palladium-containing composition and method for producing hydrogen peroxide 三菱瓦斯化学株式会社 2024-02-02 CN disclosed
CN-117285547-A Macrocyclic compounds as modulators of CFTR, pharmaceutical compositions thereof, their use and methods of preparation 弗特克斯药品有限公司 2023-12-26 CN disclosed
CN-111801398-B Process for the manufacture of secondary aliphatic alcohols, internal olefins and internal olefin sulfonates 罗地亚经营管理公司 2023-11-07 CN disclosed
WO-2003072561-A1 BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-09-04 WO disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2003-03-20 US disclosed
WO-2003020714-A1 POLYESTER POLYCARBONATES MADE FROM SPECIAL DIPHENOLS BAYER MATERIALSCIENCE AG (DE) 2003-03-13 WO disclosed
WO-2002068417-A3 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS SLASSI ABDELMALIK (CA) 2002-11-14 WO disclosed
US-20020169188-A1 Novel amines as histamine-3 receptor ligands and their therapeutic applications ABBVIE INC. 2002-11-14 US disclosed
US-20020165405-A1 Process for preparing organically-substituted polyoxometalates THE CURATORS OF THE UNIVERSITY OF MISSOURI 2002-11-07 US disclosed
WO-2002068417-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-09-06 WO disclosed
WO-2001018528-A1 METHOD OF ANALYZING MULTIPLE SAMPLES SIMULTANEOUSLY BY DETECTING ABSORPTION AND SYSTEMS FOR USE IN SUCH A METHOD IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2001-03-15 WO disclosed
WO-1996005178-A1 SYNTHESIS OF BENZODIAZEPINES IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1996-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165405-A1 Process for preparing organically-substituted polyoxometalates TET2, ALKBH3, FTO MAPT 2662/4885CYP2C9 1110/4885F3 1981/4885
US-20020169188-A1 Novel amines as histamine-3 receptor ligands and their therapeutic applications HRH3, HRH4, HRH1 MAPT 3342/4885CYP2C9 1912/4885F3 1081/4885
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists GRM2, GRIN2A, GRM1 MAPT 659/4885CYP2C9 4234/4885F3 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.